STCSM Officials Meet with CP Pharmaceutical Group President Shanghai S&T | April 11, 2023 Release time: 2023-05-30Source: SCIENCE AND TECHNOLOGY COMMISSION OF SHANGHAI MUNICIPALITY
On the afternoon of April 11, Xu Feng, secretary of the Party committee of the Science & Technology Commission of Shanghai Municipality (STCSM), and Zhu Qigao, vice chairman of STCSM, met with Zheng Xiangling, president of CP Pharmaceutical Group and chairwoman of the Hong Kong Chinese People’s Political Consultative Conference (Provincial) Members Association. The two sides had in-depth exchange of views on issues concerning science and technology innovation in biomedicine.
Xu appreciated the spectacular achievements in pharmaceutical, medical and comprehensive healthcare industries made in recent years by CP Pharmaceutical Group, an international and innovative pharmaceutical enterprise. Shanghai welcomes CP Pharmaceutical Group to, leveraging its own strengths, join in Shanghai’s innovation process, bring more high-level talent, and fuel the high-quality development of Shanghai’s biomedical industry. Both the CPC Shanghai Municipal Committee and STCSM will try their best to facilitate a better and faster growth of the Group in the city.
Zhu introduced Shanghai’s efforts to build itself into a sci-tech innovation center and the city’s latest advances in biomedical innovation. Both sides had detailed discussions about issues concerning the Group’s global research and development headquarters in Shanghai, S&T policies, commercialization of S&T achievements, platform building, and talent fostering.
Zheng introduced the development of CP Pharmaceutical Group in Shanghai and the Group’s willingness to cooperate further with the city. She said CP Pharmaceutical Group as an international enterprise will leverage its full-industry-chain strengths in biomedicine, increase R&D investment, deepen industrial cooperation, join in Shanghai’s innovation process, and contribute to the high-quality development of Shanghai’s biomedical industry.
Also present at the meeting were Eric Tse, executive director of Sino Biopharmaceutical Limited and president of Chiatai Tianqing (CTTQ) and Beijing Tide Pharmaceutical Co., Ltd, executives from CTTQ, and relevant officials from STCSM.

